Home > Oncology > ESMO 2022 > Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanoma

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanoma

Presented By
Dr Sapna Patel, MD Anderson Cancer Center, TX, USA
Conference
ESMO 2022
Trial
Phase 2, SWOG S1808
Compared with the same treatment given entirely in the adjuvant setting, neoadjuvant pembrolizumab followed by adjuvant pembrolizumab improves event-free survival in patients with resectable melanoma, first results of the SWOG S1808 trial demonstrate. A current fundamental question in the treatment of patients with resectable cancer is whether treatment with immunotherapy before surgery induces an enhanced anti-tumour immune response or simply delays curative surgery. The rationale in favour of neoadjuvant immunotherapy is that, compared with adjuvant immunotherapy, it has been shown to induce an immune response from a larger population of T cells [1]. To further prove this hypothesis, Dr Sapna Patel (MD Anderson Cancer Center, TX, USA) presented the first results of the phase 2 randomised SWOG S1808 trial (NCT03698019), which compared neoadjuvant pembrolizu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on